Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated:  7/14/2015
Don Monti Comprehensive Cancer Center at North Shore University Hospital
mi
from
Manhasset, NY
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated: 7/14/2015
Don Monti Comprehensive Cancer Center at North Shore University Hospital
mi
from
Manhasset, NY
Click here to add this to my saved trials
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated:  7/14/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated: 7/14/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated:  7/14/2015
Mount Sinai Hospital
mi
from
New York, NY
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated: 7/14/2015
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated:  7/14/2015
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated: 7/14/2015
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated:  7/14/2015
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated: 7/14/2015
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Click here to add this to my saved trials
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated:  7/14/2015
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated: 7/14/2015
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated:  7/14/2015
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University
mi
from
Columbus, OH
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated: 7/14/2015
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated:  7/14/2015
Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital
mi
from
Pittsburgh, PA
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated: 7/14/2015
Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated:  7/14/2015
Hollings Cancer Center at Medical University of South Carolina
mi
from
Charleston, SC
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated: 7/14/2015
Hollings Cancer Center at Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated:  7/14/2015
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells
Status: Enrolling
Updated: 7/14/2015
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase II Study of Alvocidib (NSC 649890, Flavopiridol) in Timed Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone for Adults With Newly Diagnosed, Previously Untreated, Poor-Risk Acute Myelogenous Leukemias
Status: Enrolling
Updated:  7/14/2015
Johns Hopkins University-Sidney Kimmel Cancer Center
mi
from
Baltimore, MD
Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase II Study of Alvocidib (NSC 649890, Flavopiridol) in Timed Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone for Adults With Newly Diagnosed, Previously Untreated, Poor-Risk Acute Myelogenous Leukemias
Status: Enrolling
Updated: 7/14/2015
Johns Hopkins University-Sidney Kimmel Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
Randomized Placebo Controlled Double Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  7/15/2015
Norwestern Memorial Hospital
mi
from
Chicago, IL
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
Randomized Placebo Controlled Double Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 7/15/2015
Norwestern Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
Randomized Placebo Controlled Double Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  7/15/2015
Vanderbilt-Ingram Cancer Center - Cool Springs
mi
from
Nashville, TN
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
Randomized Placebo Controlled Double Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 7/15/2015
Vanderbilt-Ingram Cancer Center - Cool Springs
mi
from
Nashville, TN
Click here to add this to my saved trials
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
Randomized Placebo Controlled Double Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  7/15/2015
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
Randomized Placebo Controlled Double Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 7/15/2015
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
Randomized Placebo Controlled Double Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  7/15/2015
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
Randomized Placebo Controlled Double Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 7/15/2015
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
Randomized Placebo Controlled Double Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  7/15/2015
Stanford University
mi
from
Palo Alto, CA
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
Randomized Placebo Controlled Double Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 7/15/2015
Stanford University
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
Randomized Placebo Controlled Double Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  7/15/2015
M D Anderson Cancer Center
mi
from
Houston, TX
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
Randomized Placebo Controlled Double Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 7/15/2015
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
Phase II Randomized Study of Low-Dose Decitabine (5-AZA-2'-Deoxycytidine) With or Without Valproic Acid in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia -"SPORE"
Status: Enrolling
Updated:  7/15/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
Phase II Randomized Study of Low-Dose Decitabine (5-AZA-2'-Deoxycytidine) With or Without Valproic Acid in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia -"SPORE"
Status: Enrolling
Updated: 7/15/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Comparative Trial of Cryotherapy Versus Caphosol Versus Saline Solution Mouth Washes for the Prevention of Oral Mucositis in Patients With Multiple Myeloma Undergoing Hematopoietic Stem Cell Transplantation
A Prospective, Randomized, Comparative Trial of Cryotherapy Versus Caphosol Versus Saline Solution Mouth Washes for the Prevention of Oral Mucositis in Patients With Multiple Myeloma Undergoing Hematopoietic Stem Cell Transplantation.
Status: Enrolling
Updated:  7/16/2015
South Texas Veterans Health Care System
mi
from
San Antonio, TX
Comparative Trial of Cryotherapy Versus Caphosol Versus Saline Solution Mouth Washes for the Prevention of Oral Mucositis in Patients With Multiple Myeloma Undergoing Hematopoietic Stem Cell Transplantation
A Prospective, Randomized, Comparative Trial of Cryotherapy Versus Caphosol Versus Saline Solution Mouth Washes for the Prevention of Oral Mucositis in Patients With Multiple Myeloma Undergoing Hematopoietic Stem Cell Transplantation.
Status: Enrolling
Updated: 7/16/2015
South Texas Veterans Health Care System
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma
BrUOG 273:Cellular Immunotherapy For Refractory Hematological Malignancies:A Brown University Oncology Research Group Study
Status: Enrolling
Updated:  7/17/2015
Rhode Island Hospital
mi
from
Providence, RI
Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma
BrUOG 273:Cellular Immunotherapy For Refractory Hematological Malignancies:A Brown University Oncology Research Group Study
Status: Enrolling
Updated: 7/17/2015
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma
BrUOG 273:Cellular Immunotherapy For Refractory Hematological Malignancies:A Brown University Oncology Research Group Study
Status: Enrolling
Updated:  7/17/2015
Miriam Hospital
mi
from
Providence, RI
Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma
BrUOG 273:Cellular Immunotherapy For Refractory Hematological Malignancies:A Brown University Oncology Research Group Study
Status: Enrolling
Updated: 7/17/2015
Miriam Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Efficacy of a Patient Education Video
Efficacy of a Patient Education Video
Status: Enrolling
Updated:  7/17/2015
Virginia Commonwealth University
mi
from
Richmond, VA
Efficacy of a Patient Education Video
Efficacy of a Patient Education Video
Status: Enrolling
Updated: 7/17/2015
Virginia Commonwealth University
mi
from
Richmond, VA
Click here to add this to my saved trials
Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
HO11415: Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
Status: Enrolling
Updated:  7/22/2015
University of Wisconsin Carbone Cancer Center
mi
from
Madison, WI
Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
HO11415: Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
Status: Enrolling
Updated: 7/22/2015
University of Wisconsin Carbone Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma
A Phase 2 Study of AZD6244 in Multiple Myeloma
Status: Enrolling
Updated:  7/24/2015
Moffitt Cancer Center
mi
from
Tampa, FL
AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma
A Phase 2 Study of AZD6244 in Multiple Myeloma
Status: Enrolling
Updated: 7/24/2015
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma
A Phase 2 Study of AZD6244 in Multiple Myeloma
Status: Enrolling
Updated:  7/24/2015
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma
A Phase 2 Study of AZD6244 in Multiple Myeloma
Status: Enrolling
Updated: 7/24/2015
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma
A Phase 2 Study of AZD6244 in Multiple Myeloma
Status: Enrolling
Updated:  7/24/2015
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma
A Phase 2 Study of AZD6244 in Multiple Myeloma
Status: Enrolling
Updated: 7/24/2015
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma
A Phase 2 Study of AZD6244 in Multiple Myeloma
Status: Enrolling
Updated:  7/24/2015
Mark O Hatfield-Warren Grant Magnuson Clinical Center
mi
from
Bethesda, MD
AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma
A Phase 2 Study of AZD6244 in Multiple Myeloma
Status: Enrolling
Updated: 7/24/2015
Mark O Hatfield-Warren Grant Magnuson Clinical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma
A Phase 2 Study of AZD6244 in Multiple Myeloma
Status: Enrolling
Updated:  7/24/2015
National Institutes of Health
mi
from
Bethesda, MD
AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma
A Phase 2 Study of AZD6244 in Multiple Myeloma
Status: Enrolling
Updated: 7/24/2015
National Institutes of Health
mi
from
Bethesda, MD
Click here to add this to my saved trials
AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma
A Phase 2 Study of AZD6244 in Multiple Myeloma
Status: Enrolling
Updated:  7/24/2015
Billings Clinic Cancer Center
mi
from
Billings, MT
AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma
A Phase 2 Study of AZD6244 in Multiple Myeloma
Status: Enrolling
Updated: 7/24/2015
Billings Clinic Cancer Center
mi
from
Billings, MT
Click here to add this to my saved trials
AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma
A Phase 2 Study of AZD6244 in Multiple Myeloma
Status: Enrolling
Updated:  7/24/2015
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma
A Phase 2 Study of AZD6244 in Multiple Myeloma
Status: Enrolling
Updated: 7/24/2015
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma
A Phase 2 Study of AZD6244 in Multiple Myeloma
Status: Enrolling
Updated:  7/24/2015
Vanderbilt University/Ingram Cancer Center
mi
from
Nashville, TN
AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma
A Phase 2 Study of AZD6244 in Multiple Myeloma
Status: Enrolling
Updated: 7/24/2015
Vanderbilt University/Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma
A Phase 2 Study of AZD6244 in Multiple Myeloma
Status: Enrolling
Updated:  7/24/2015
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma
A Phase 2 Study of AZD6244 in Multiple Myeloma
Status: Enrolling
Updated: 7/24/2015
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)
A Study to Infuse ROR1-Specific Autologous T Cells for Patients With Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)
Status: Enrolling
Updated:  7/27/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)
A Study to Infuse ROR1-Specific Autologous T Cells for Patients With Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)
Status: Enrolling
Updated: 7/27/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia
Lenalidomide in Combination With Rituximab as Treatment for Patients With Relapsed Chronic Lymphocytic Leukemia - RV-CLL-PI-0292
Status: Enrolling
Updated:  7/27/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia
Lenalidomide in Combination With Rituximab as Treatment for Patients With Relapsed Chronic Lymphocytic Leukemia - RV-CLL-PI-0292
Status: Enrolling
Updated: 7/27/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Aflibercept for Relapsed Multiple Myeloma
A Phase 2 Study of Aflibercept for the Treatment of Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  7/28/2015
Albert Einstein College of Medicine
mi
from
Bronx, NY
Aflibercept for Relapsed Multiple Myeloma
A Phase 2 Study of Aflibercept for the Treatment of Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 7/28/2015
Albert Einstein College of Medicine
mi
from
Bronx, NY
Click here to add this to my saved trials
Aflibercept for Relapsed Multiple Myeloma
A Phase 2 Study of Aflibercept for the Treatment of Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  7/28/2015
North Shore University Hospital
mi
from
Manhasset, NY
Aflibercept for Relapsed Multiple Myeloma
A Phase 2 Study of Aflibercept for the Treatment of Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 7/28/2015
North Shore University Hospital
mi
from
Manhasset, NY
Click here to add this to my saved trials
Aflibercept for Relapsed Multiple Myeloma
A Phase 2 Study of Aflibercept for the Treatment of Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  7/28/2015
Columbia University Medical Center
mi
from
New York, NY
Aflibercept for Relapsed Multiple Myeloma
A Phase 2 Study of Aflibercept for the Treatment of Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 7/28/2015
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Aflibercept for Relapsed Multiple Myeloma
A Phase 2 Study of Aflibercept for the Treatment of Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  7/28/2015
Weill Medical College of Cornell University
mi
from
New York, NY
Aflibercept for Relapsed Multiple Myeloma
A Phase 2 Study of Aflibercept for the Treatment of Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 7/28/2015
Weill Medical College of Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Aflibercept for Relapsed Multiple Myeloma
A Phase 2 Study of Aflibercept for the Treatment of Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  7/28/2015
Mount Sinai Hospital
mi
from
New York, NY
Aflibercept for Relapsed Multiple Myeloma
A Phase 2 Study of Aflibercept for the Treatment of Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 7/28/2015
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Aflibercept for Relapsed Multiple Myeloma
A Phase 2 Study of Aflibercept for the Treatment of Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  7/28/2015
Montefiore Medical Center
mi
from
Bronx, NY
Aflibercept for Relapsed Multiple Myeloma
A Phase 2 Study of Aflibercept for the Treatment of Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 7/28/2015
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Tandem Auto-Allo Transplant for Lymphoma
Sequential Myeloablative Autologous Stem Cell Transplantation Followed by Allogeneic Non-Myeloablative Stem Cell Transplantation for Patients With Poor Risk Lymphomas
Status: Enrolling
Updated:  7/28/2015
Massachusetts General Hospital
mi
from
Boston, MA
Tandem Auto-Allo Transplant for Lymphoma
Sequential Myeloablative Autologous Stem Cell Transplantation Followed by Allogeneic Non-Myeloablative Stem Cell Transplantation for Patients With Poor Risk Lymphomas
Status: Enrolling
Updated: 7/28/2015
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Tandem Auto-Allo Transplant for Lymphoma
Sequential Myeloablative Autologous Stem Cell Transplantation Followed by Allogeneic Non-Myeloablative Stem Cell Transplantation for Patients With Poor Risk Lymphomas
Status: Enrolling
Updated:  7/28/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Tandem Auto-Allo Transplant for Lymphoma
Sequential Myeloablative Autologous Stem Cell Transplantation Followed by Allogeneic Non-Myeloablative Stem Cell Transplantation for Patients With Poor Risk Lymphomas
Status: Enrolling
Updated: 7/28/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Patient Reported Outcomes in Chronic Myeloid Leukemia
Patient Reported Outcomes in Chronic Myeloid Leukemia. GIMEMA QoL - CML0310.
Status: Enrolling
Updated:  7/29/2015
Dana-Farber Cancer Institute Harvard University
mi
from
Boston, MA
Patient Reported Outcomes in Chronic Myeloid Leukemia
Patient Reported Outcomes in Chronic Myeloid Leukemia. GIMEMA QoL - CML0310.
Status: Enrolling
Updated: 7/29/2015
Dana-Farber Cancer Institute Harvard University
mi
from
Boston, MA
Click here to add this to my saved trials
Patient Reported Outcomes in Chronic Myeloid Leukemia
Patient Reported Outcomes in Chronic Myeloid Leukemia. GIMEMA QoL - CML0310.
Status: Enrolling
Updated:  7/29/2015
Innsbruck University Hospital
mi
from
Innsbruck,
Patient Reported Outcomes in Chronic Myeloid Leukemia
Patient Reported Outcomes in Chronic Myeloid Leukemia. GIMEMA QoL - CML0310.
Status: Enrolling
Updated: 7/29/2015
Innsbruck University Hospital
mi
from
Innsbruck,
Click here to add this to my saved trials
Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML
A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects With Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic Myelogenous Leukemia Who Are Resistant or Intolerant to Imatinib Mesylate (Gleevec)
Status: Enrolling
Updated:  7/29/2015
University of Alabama at Birmingham
mi
from
Birmingham, AL
Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML
A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects With Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic Myelogenous Leukemia Who Are Resistant or Intolerant to Imatinib Mesylate (Gleevec)
Status: Enrolling
Updated: 7/29/2015
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML
A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects With Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic Myelogenous Leukemia Who Are Resistant or Intolerant to Imatinib Mesylate (Gleevec)
Status: Enrolling
Updated:  7/29/2015
Central Hematology/Oncology Medical Group, Inc.
mi
from
Alhambra, CA
Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML
A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects With Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic Myelogenous Leukemia Who Are Resistant or Intolerant to Imatinib Mesylate (Gleevec)
Status: Enrolling
Updated: 7/29/2015
Central Hematology/Oncology Medical Group, Inc.
mi
from
Alhambra, CA
Click here to add this to my saved trials
Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML
A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects With Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic Myelogenous Leukemia Who Are Resistant or Intolerant to Imatinib Mesylate (Gleevec)
Status: Enrolling
Updated:  7/29/2015
Pacific Cancer Medical Center
mi
from
Anaheim, CA
Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML
A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects With Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic Myelogenous Leukemia Who Are Resistant or Intolerant to Imatinib Mesylate (Gleevec)
Status: Enrolling
Updated: 7/29/2015
Pacific Cancer Medical Center
mi
from
Anaheim, CA
Click here to add this to my saved trials
Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML
A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects With Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic Myelogenous Leukemia Who Are Resistant or Intolerant to Imatinib Mesylate (Gleevec)
Status: Enrolling
Updated:  7/29/2015
Loma Linda University Cancer Center
mi
from
Loma Linda, CA
Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML
A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects With Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic Myelogenous Leukemia Who Are Resistant or Intolerant to Imatinib Mesylate (Gleevec)
Status: Enrolling
Updated: 7/29/2015
Loma Linda University Cancer Center
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML
A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects With Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic Myelogenous Leukemia Who Are Resistant or Intolerant to Imatinib Mesylate (Gleevec)
Status: Enrolling
Updated:  7/29/2015
Pacific Shores Medical Group
mi
from
Long Beach, CA
Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML
A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects With Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic Myelogenous Leukemia Who Are Resistant or Intolerant to Imatinib Mesylate (Gleevec)
Status: Enrolling
Updated: 7/29/2015
Pacific Shores Medical Group
mi
from
Long Beach, CA
Click here to add this to my saved trials
Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML
A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects With Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic Myelogenous Leukemia Who Are Resistant or Intolerant to Imatinib Mesylate (Gleevec)
Status: Enrolling
Updated:  7/29/2015
Ucla Dept. Of Medicine
mi
from
Los Angeles, CA
Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML
A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects With Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic Myelogenous Leukemia Who Are Resistant or Intolerant to Imatinib Mesylate (Gleevec)
Status: Enrolling
Updated: 7/29/2015
Ucla Dept. Of Medicine
mi
from
Los Angeles, CA
Click here to add this to my saved trials